Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Notch

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Notch. Displaying page 1 of 1.
    EudraCT Number: 2019-000309-64 Sponsor Protocol Number: AL-ACC-01 Start Date*: 2019-10-24
    Sponsor Name:Ayala Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-Label, Multi-Center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
    Medical condition: Adenoid cystic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053231 Adenoid cystic carcinoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002286-30 Sponsor Protocol Number: A8641020 Start Date*: 2014-12-12
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: PHASE 2 STUDY OF SINGLE-AGENT PF 03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS
    Medical condition: ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended) IT (Completed) BE (Prematurely Ended) ES (Completed) DE (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004544-10 Sponsor Protocol Number: AUT-001 Start Date*: 2017-09-18
    Sponsor Name:Audion Therapeutics BV
    Full Title: A phase I/II multiple ascending dose open-label safety and efficacy study of the Notch Inhibitor LY3056480 in patients with mild to moderate sensorineural hearing loss.
    Medical condition: Sensorineural hearing loss (SNHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004854 10040016 Sensorineural hearing loss LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001491-35 Sponsor Protocol Number: CB103-C-101 Start Date*: 2017-08-11
    Sponsor Name:Cellestia Biotech AG
    Full Title: A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adu...
    Medical condition: advanced or metastatic solid tumours and haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001979-33 Sponsor Protocol Number: AL-TNBC-01 Start Date*: 2020-12-16
    Sponsor Name:Ayala Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multicenter, Open-label, Single-arm Study of AL101 Monotherapy in Patients with Notch-activated Triple Negative Breast Cancer
    Medical condition: Notch Activated Recurrent or Metastatic Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-000985-19 Sponsor Protocol Number: Start Date*: 2007-07-04
    Sponsor Name:University of Leuven
    Full Title: the effect of simvastatin (Zocor) on enhancement of ocular blood flow in glaucoma patients
    Medical condition: glaucoma patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004346-17 Sponsor Protocol Number: 06-003, Incorporating Amendts 1+2 Start Date*: 2008-02-19
    Sponsor Name:Mediquest Therapeutics Inc
    Full Title: Phase IIB Dose Response and Safety Study of Topical Formulations of Methotrexate (MQX-5902, MQX-5904 and MQX-5906) in the Treatment of Fingernail Psoriasis
    Medical condition: Psoriasis of the fingernail
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000424-25 Sponsor Protocol Number: 1508175 Start Date*: 2016-04-12
    Sponsor Name:CHU Saint-Etienne
    Full Title: Low-molecular-weight heparin in constituted vascular intrauterine growth restriction. Randomized multicenter trial
    Medical condition: Intrauterine growth restriction (IUGR)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10022819 Intrauterine growth retardation LLT
    20.0 100000004868 10048489 Intrauterine growth retard LLT
    20.0 100000004868 10048488 Growth intrauterine retard LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004933-19 Sponsor Protocol Number: DROPROP1 Start Date*: Information not available in EudraCT
    Sponsor Name:Region Västra Götaland, Sahlgrenska Universitetssjukhuset
    Full Title: A Randomized Intervention, Multi-Center Study to Determine the Role of Dexamethasone eye drops against proliferative retinopathy of prematurity
    Medical condition: Retinopathy of Prematurity
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10036858 Proliferative retinopathy LLT
    Population Age: Preterm newborn infants, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005024-10 Sponsor Protocol Number: I6F-MC-JJCB Start Date*: 2015-07-29
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients
    Medical condition: T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-009470-27 Sponsor Protocol Number: Version 1 20/11/2008 Start Date*: 2009-06-01
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: PHASE II TRIAL OF THE EFFECT OF GEMCITABINE WITH INTRAVENOUS OMEGA 3 FISH OIL INFUSION IN PATIENTS WITH UNRESECTABLE PANCREATIC ADENOCARCINOMA.
    Medical condition: Advanced pancreatic adenocarcinoma - histologically/cytologically confirmed pancreatic adenocarcinoma which is not surgically resectable, in patients suitable for gemcitabine chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033610 Pancreatic carcinoma metastatic LLT
    9.1 10033611 Pancreatic carcinoma non-resectable LLT
    9.1 10033610 Pancreatic carcinoma metastatic PT
    9.1 10033611 Pancreatic carcinoma non-resectable PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002833-39 Sponsor Protocol Number: CHUBX2017/52 Start Date*: 2018-12-12
    Sponsor Name:CHU DE BORDEAUX
    Full Title: A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as pre-operative treatment for locally recurrent rectal cancer (GRECCAR – PRODIGE ...
    Medical condition: Recurrent rectal cancer after local excision
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004358-32 Sponsor Protocol Number: IJB–TNBC–1–RHEA Start Date*: 2015-05-07
    Sponsor Name:Institut Jules Bordet
    Full Title: Biomarker Research Study for PF-03084014 in cHEmoresistant triple negative breast cAncer - “RHEA” study
    Medical condition: patients with chemoresistant, triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003248-10 Sponsor Protocol Number: bb2121-MM-007 Start Date*: 2021-02-09
    Sponsor Name:Celgene Corporation
    Full Title: An exploratory phase 1/2 trial to determine recommended phase 2 dose (RP2D), safety and preliminary efficacy of bb2121 (ide-cel) combinations in subjects with refractory/relapsed multiple myeloma
    Medical condition: Multiple myeloma (MM) with progression during or within 6 months of the last treatment.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    21.1 100000004864 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010067-16 Sponsor Protocol Number: CN156018 Start Date*: 2009-07-08
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal ...
    Medical condition: ALZHEIMER DISEASE
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 09:40:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA